During the coronavirus disease 2019 (COVID-19) pandemic, patients with humoral immunodeficiency are at higher risk of developing chronic infection and having a negative outcome. Few data are available on therapeutic options for this population. This case report discusses the treatment of disease relapse with remdesivir and monoclonal antibodies in an adult patient with X-linked agammaglobulinaemia.

Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia / E. Palomba, M. Carrabba, G. Zuglian, L. Alagna, P. Saltini, V. Fortina, C. Hu, A. Bandera, G. Fabio, A. Gori, A. Muscatello. - In: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES. - ISSN 1201-9712. - 110:(2021 Sep), pp. 338-340. [10.1016/j.ijid.2021.07.064]

Treatment of SARS-CoV-2 relapse with remdesivir and neutralizing antibodies cocktail in a patient with X-linked agammaglobulinaemia

E. Palomba
Primo
;
P. Saltini;V. Fortina;C. Hu;A. Bandera;G. Fabio;A. Gori
Penultimo
;
2021

Abstract

During the coronavirus disease 2019 (COVID-19) pandemic, patients with humoral immunodeficiency are at higher risk of developing chronic infection and having a negative outcome. Few data are available on therapeutic options for this population. This case report discusses the treatment of disease relapse with remdesivir and monoclonal antibodies in an adult patient with X-linked agammaglobulinaemia.
Casirivimab; COVID-19; Imdevimab; Immunocompromised; Monoclonal antibodies; Neutralizing antibodies; Remdesivir; SARS-CoV-2; XLA; Adenosine Monophosphate; Adult; Agammaglobulinemia; Alanine; Antibodies, Neutralizing; Antibodies, Viral; Genetic Diseases, X-Linked; Humans; Recurrence; COVID-19; SARS-CoV-2
Settore MED/17 - Malattie Infettive
set-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1201971221006196-main.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 603.49 kB
Formato Adobe PDF
603.49 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/899769
Citazioni
  • ???jsp.display-item.citation.pmc??? 16
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 13
social impact